ELISA-Based Neonatal Screening Line Offers Menu of Eight Kits

By LabMedica International staff writers
Posted on 25 Jun 2018
A recently released line of ELISA tests for neonatal screening is based on Dry Blood Spot (DBS) technology and comprises a menu of eight kits. The kits are the newest diagnostic assays being introduced by Calbiotech (Spring Valley, CA, USA).

The Calbiotech catalog features over 200 diagnostic products including a full range of ELISA-based immunoassay kits focused on areas such as: thyroid hormones, fertility, steroids, diabetes, allergy, anemia, growth markers, bone metabolism, inflammatory diseases, cancer, cardiac diseases, drugs of abuse, autoimmune disorders, infectious diseases, and neonatal screening.

Image: The new line of ELISA tests designed for neonatal screening is based on Dry Blood Spot (DBS) technology and comprises a menu of eight kits (Photo courtesy of Calbiotech).

In addition, Calbiotech's Custom Development team crafts custom assays in a "Pipeline to Production" approach. To this end, the company has developed coated microplates, reagents, buffers, and other components for pharmaceutical companies, universities, and research centers in the United States and around the world. Rounding out its contribution to the diagnostics industry, Calbiotech also offers contract-manufacturing services that cover immunoassay development (microplates and magnetic beads), bulk coating of microplates, reagent preparation, including bottling, labeling and packaging.


Latest Molecular Diagnostics News